In this study, we investigated potential peripheral blood biomarkers associated with therapeutic efficacy of ICIs plus chemotherapy in advanced NSCLC patients without sensitive EGFR/ALK/ROS1 alterations. Here, ROS1 is linked to non-small cell lung carcinoma.